Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAGXNASDAQ:ONCONASDAQ:QLGNNASDAQ:VIRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Animal Health$2.57-0.2%$5.41$2.43▼$110.75$2.62M0.5654,173 shs17,887 shsONCOOnconetix$4.65-4.2%$5.82$3.82▼$1,190.00$2.46M3.38114,208 shs63,918 shsQLGNQualigen Therapeutics$3.260.0%$3.66$2.85▼$29.44$5.35M0.0388,525 shs4,783 shsVIRXViracta Therapeutics$0.02+1.3%$0.02$0.01▼$0.58$644K1.061.08 million shs31,733 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Animal Health0.00%+2.60%-36.82%-46.45%-97.14%ONCOOnconetix0.00%-3.83%-26.25%-24.10%-99.12%QLGNQualigen Therapeutics0.00%-8.69%-13.09%+3.79%-76.72%VIRXViracta Therapeutics0.00%-8.99%-4.71%-28.63%-96.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAGXJaguar Animal Health1.8429 of 5 stars3.53.00.00.00.90.00.6ONCOOnconetix0.2899 of 5 stars0.04.00.00.00.00.00.6QLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVIRXViracta Therapeutics2.1113 of 5 stars3.25.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar Animal Health 3.00Buy$60.002,239.18% UpsideONCOOnconetix 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/AVIRXViracta Therapeutics 2.33Hold$1.7510,702.47% UpsideCurrent Analyst Ratings BreakdownLatest VIRX, QLGN, ONCO, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Animal Health$11.69M0.22N/AN/A$12.29 per share0.21ONCOOnconetix$2.52M0.98N/AN/A$11.22 per share0.41QLGNQualigen Therapeutics$4.98M1.07N/AN/A($4.12) per share-0.79VIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)ONCOOnconetix-$58.69MN/A0.00∞N/A-2,913.71%-514.04%-75.82%8/27/2025 (Estimated)QLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/AN/A8/13/2025 (Estimated)VIRXViracta Therapeutics-$51.06M-$1.10N/A∞N/AN/A-1,899.61%-114.21%8/12/2025 (Estimated)Latest VIRX, QLGN, ONCO, and JAGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 million5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar Animal HealthN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Animal Health22.201.080.70ONCOOnconetixN/A0.170.16QLGNQualigen TherapeuticsN/A2.332.33VIRXViracta TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Animal Health12.04%ONCOOnconetix23.89%QLGNQualigen Therapeutics3.18%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipJAGXJaguar Animal Health0.38%ONCOOnconetix3.10%QLGNQualigen Therapeutics1.80%VIRXViracta Therapeutics10.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Animal Health501.02 million1.01 millionNo DataONCOOnconetix12530,000516,000N/AQLGNQualigen Therapeutics501.64 million1.61 millionNot OptionableVIRXViracta Therapeutics2039.74 million35.50 millionOptionableVIRX, QLGN, ONCO, and JAGX HeadlinesRecent News About These CompaniesCalif. biotech company once worth $476M lays off every remaining employeeFebruary 11, 2025 | msn.comViracta Therapeutics Terminates Employees & Winds Down OperationsFebruary 8, 2025 | contractpharma.comCViracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of OperationsFebruary 6, 2025 | finanznachrichten.deViracta Therapeutics Shuts Down Operations, Lays Off All StaffFebruary 6, 2025 | precisionmedicineonline.comPViracta Therapeutics terminates employees, to wind down operationsFebruary 6, 2025 | markets.businessinsider.comViracta Therapeutics to cease operations and seek alternativesFebruary 5, 2025 | msn.comViracta Therapeutics Winds Down Operations, Terminates EmployeesFebruary 5, 2025 | marketwatch.comViracta Therapeutics hits end of the line, laying off all workers and winding downFebruary 5, 2025 | fiercebiotech.comFViracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of OperationsFebruary 5, 2025 | quiverquant.comQViracta Therapeutics Announces Wind Down of OperationsFebruary 5, 2025 | globenewswire.comWhy Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?February 4, 2025 | bovnews.comBVIRX stock plunges to 52-week low, touches $0.08February 3, 2025 | msn.comViracta Therapeutics to be delisted from NasdaqFebruary 3, 2025 | msn.comViracta Therapeutics strikes deal to avoid defaultJanuary 25, 2025 | msn.comViracta Therapeutics Inc (VIRX) Stock Trading RecapJanuary 10, 2025 | bovnews.comBVIRX’s Unexpected Surge: What’s Next?January 6, 2025 | bovnews.comBViracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?January 3, 2025 | bovnews.comBCash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining optionsJanuary 3, 2025 | fiercebiotech.comFLeerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) StockDecember 30, 2024 | bovnews.comBServiceTitan initiated, Viracta downgraded: Wall Street's top analyst callsDecember 27, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIRX, QLGN, ONCO, and JAGX Company DescriptionsJaguar Animal Health NASDAQ:JAGX$2.56 -0.01 (-0.19%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$2.60 +0.04 (+1.52%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Onconetix NASDAQ:ONCO$4.64 -0.21 (-4.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$4.55 -0.09 (-2.05%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Qualigen Therapeutics NASDAQ:QLGN$3.26 0.00 (-0.03%) Closing price 07/3/2025 03:10 PM EasternExtended Trading$3.26 0.00 (-0.09%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Viracta Therapeutics NASDAQ:VIRX$0.02 +0.00 (+1.25%) As of 07/3/2025 12:58 PM EasternViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
